HEPA - Hepion Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HEPA

HEPION PHARMACEUTICALS, INC.

OTC

$0.10

▲ UP 79.25% (0.04)

KEY STATISTICS

Market Cap$1.11 M

52w High$0.11

52w Low$0.03

Dividend Yield—

Frequency—

P/E-0.04

Volume208.11K

Shares Out.11.64M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Gary S. Stetz

COMPENSATION 2026

Salary$232,500

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$232,500

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 10, 2014

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$70.00

Target Low$70.00

Target Median$70.00

Target Consensus$70.00

UPCOMING EARNINGS

DateOct 14, 2026

DayWednesday

Rev. Est.—

OCT

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-03-18	Reverse	1:50
2023-05-11	Reverse	1:20
2019-06-03	Reverse	1:70
2018-05-29	Reverse	1:8

PRICE

$0.10 ▲ UP 79.25% (+$0.04)

OVERLAYS

About Hepion Pharmaceuticals, Inc.

https://www.hepionpharma.com ↗

Hepion Pharmaceuticals develops drug therapies, including Rencofilstat, for chronic liver diseases like NASH, fibrosis, and hepatitis, with ongoing clinical trials and antiviral research.

INDUSTRY

Biotechnology

A PRODUCT HEPION PHARMACEUTICALS, INC. IS KNOWN FOR

Rencofilstat (CRV431)

Rencofilstat is an investigational cyclophilin inhibitor evaluated in Phase 2 trials for NASH and HCC, but the company is winding down its NASH program and selling related assets due to resource constraints.